Rapid Evolution Of Cardiovascular Device Therapies For Atrial Fibrillation And Heart Failure To Disrupt The Cardiac Implants Market
Cardiac implants market of atrial fibrillation (AF) and heart failure (HF) is rapidly evolving with the implementation of innovative materials and new technologies. In 2009, HeartWare Ventricular Assist System received European CE approval followed by the Australian Therapeutic Goods Administration (TGA)in 2011 and U.S. Food and Drug Administration (FDA) in 2012, acquires the major portion of implantable ventricular assist devices (VAD) market outside the United States. On the basis of the analysis by Goldstein Research data scientists, global demand for cardiac implants will grow by 10.1% over the forecast period, rebounding from a slowdown caused by product recalls and safety controversies. Pacing devices tend to dominate the market, with gains followed by CRT devices. On the other hand, stents and accessories are anticipated to be the fastest growing segment owing to improved designs with reduced risk of complications. Download Exclusive Sample Report : https://www.goldsteinre...